U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept)

May 15, 2012 11:00 AM Eastern Daylight Time

U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept)

State-of the art Manufacturing Facility Supports Company's Growing Focus on Biologics

NEW YORK--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA® (abatacept).

The Devens facility, a state-of-the-art bulk biologics manufacturing facility, employs roughly 300 scientists, engineers, bioprocess operators, quality specialists and other skilled workers.

"The approval of our Devens site is an important milestone for Bristol-Myers Squibb as part of our strategic focus on delivering innovative biologic medicines for patients with serious disease," said Lou Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb. "The increased manufacturing capacity from the Devens site will support market demand for ORENCIA and positions us well for future production of additional biologic medicines."

Bristol-Myers Squibb currently manufactures its biologic medicines in a company-owned facility in Syracuse, NY and through third party suppliers, and finishes and packages them in Manati, Puerto Rico. The Syracuse site will remain a key component of the company's biologics strategy and will serve as a center of excellence in process development and early product launch for the company's biologic medicines.

"Bristol-Myers Squibb is committed to building a strong manufacturing capability to support our growing biologics portfolio, and Devens is a key component of this strategy," said Peter Moesta, senior vice president, Biologics Manufacturing and Process Development.

In 2010, the company announced the Devens facility received Leadership in Energy and Environmental Design (LEED®) Silver certification while the laboratory and office building at the same facility received LEED Gold certification in December 2009. LEED certification, established by U.S. Green Building Council and verified by the Green Building Certification Institute, is the nation's preeminent program for the design, construction and operation of high performance green buildings.
 

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.